Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BASF AG
Digital Health Roundup, August/September 2021: Record Digital Health Funding Q1-3 Of $21.3Bn, AAOS Highlights, Regulatory Updates
In this roundup of developments in digital health, we highlight the key news and announcements from August and September.
Idorsia's Fabry Drug Founders In Phase III
The prospects of lucerastat becoming Idorsia's second drug to be filed with regulators, after the insomnia treatment daridorexant, look slim after a Phase III fail for the Fabry disease therapy.
Vedanta Phase II Data Position It To Chase Seres In C. Difficile Recurrence
Vedanta thinks its live biotherapeutic sourced from clonal cell banking could offer strong prevention against C. difficile infections after antibiotics have cleared an initial infection.
US Regulatory Roundup, September 2021: Product Safety, Pediatric Devices, EUAs Revoked, And More
With news of high-risk medical device recalls and troubles with COVID-19 diagnostics, product safety was of paramount concern to Medtech Insight readers in September. Also topping the most-read list were articles focused on pediatric patients, the revocation of emergency use authorizations for products to treat and diagnose COVID-19, and more.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Pronova BioPharma
- Chemetall
- Solvay S.A.